Vis enkel innførsel

dc.contributor.authorFarup, Per Grønaas
dc.contributor.authorAasbrenn, Martin
dc.contributor.authorValeur, Jørgen
dc.coverage.spatialNorwaynb_NO
dc.date.accessioned2019-12-20T09:42:42Z
dc.date.available2019-12-20T09:42:42Z
dc.date.created2018-12-03T18:51:32Z
dc.date.issued2018
dc.identifier.citationFarup et al. BMC Obesity (2018) 5:30nb_NO
dc.identifier.issn2052-9538
dc.identifier.urihttp://hdl.handle.net/11250/2634242
dc.description.abstractBACKGROUND: Faecal dysbiosis associated with the use of metformin has been conceived as a favourable ("good") dysbiosis and that with intake of non-nutritive sweeteners (NNS) as unfavourable ("bad"). The study aimed to construct an alternative dysbiosis index (ADI) for the separation of the dysbioses into "good" and "bad", and to validate the ADI. METHODS: Subjects with morbid obesity were included. Use of NNS and drugs were noted, IBS was classified according to the Rome III criteria and the severity measured with the Irritable bowel severity scoring system (IBSSS). Faecal dysbiosis was tested with GA-Map ™ Dysbiosis test (Genetic Analysis AS, Oslo, Norway). The result was given as Dysbiosis Index (DI) scores 1-5, score > 2 indicates dysbiosis. An ADI was constructed and validated in subjects with IBS at another hospital. RESULTS: Seventy-six women and 14 men aged 44.7 years (SD 8.6) with BMI 41.8 kg/m2 (SD 3.6) were included. Dysbiosis was associated with the use of NNS and metformin, but not with IBS or IBSSS. An ADI based on differences in 7 bacteria was positively and negatively associated with the "good" metformin dysbiosis and the "bad" NNS dysbiosis respectively. The ADI was also negatively associated with IBSSS (a "bad" dysbiosis). The negative associations between ADI and IBS and IBSS were confirmed in the validation group. CONCLUSIONS: The new ADI, but not the DI, allowed separation of the "good" and "bad" faecal dysbiosis. Rather than merely reporting dysbiosis and degrees of dysbiosis, future diagnostic tests should distinguish between types of dysbiosis.nb_NO
dc.description.sponsorshipThe work was supported by a grant from Innlandet Hospital Trust, Brumunddal; and Lovisenberg Diaconal Hospital, Oslo; Norway. Genetic Analysis AS, Oslo, Norway performed the dysbiosis tests free of charge.nb_NO
dc.language.isoengnb_NO
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.subjectDysbiosis; Irritable bowel syndrome; Metformin; Microbiota; Non-nutritive sweeteners; obesitynb_NO
dc.titleSeparating “good” from “bad” faecal dysbiosis – evidence from two cross-sectional studiesnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.rights.holder© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.nb_NO
dc.source.pagenumber1-10nb_NO
dc.source.volume5nb_NO
dc.source.journalBMC Obesitynb_NO
dc.source.issue30nb_NO
dc.identifier.doi10.1186/s40608-018-0207-3
dc.identifier.cristin1638643
cristin.unitcode1991,0,0,0
cristin.unitcode1991,3,0,0
cristin.unitnameSykehuset Innlandet HF
cristin.unitnameDiv Gjøvik
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal